Published in Nature on March 11, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol (2010) 2.76
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68
Engineering synthetic vaccines using cues from natural immunity. Nat Mater (2013) 1.48
Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol (2010) 1.45
Very few substitutions in a germ line antibody are required to initiate significant domain exchange. J Virol (2010) 1.41
Innate immune sensing of HIV-1 by dendritic cells. Cell Host Microbe (2012) 1.35
Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol (2012) 1.33
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. J Virol (2012) 1.29
B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun (2010) 1.26
Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. J Exp Med (2011) 1.22
Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol (2010) 1.21
Redesigning the AIDS response for long-term impact. Bull World Health Organ (2011) 1.17
Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet (2012) 1.14
Immune activation and collateral damage in AIDS pathogenesis. Front Immunol (2013) 1.08
Single-chain Fv-based anti-HIV proteins: potential and limitations. J Virol (2011) 1.07
Persistent enteric murine norovirus infection is associated with functionally suboptimal virus-specific CD8 T cell responses. J Virol (2013) 1.05
Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J Immunol (2011) 1.04
A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses. PLoS One (2011) 1.00
CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis. Infect Immun (2011) 1.00
Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity. J Virol (2011) 0.99
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. J Acquir Immune Defic Syndr (2012) 0.97
Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. AIDS (2013) 0.96
Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice. J Virol (2010) 0.95
Negative selection by an endogenous retrovirus promotes a higher-avidity CD4+ T cell response to retroviral infection. PLoS Pathog (2012) 0.95
Early antigen presentation of protective HIV-1 KF11Gag and KK10Gag epitopes from incoming viral particles facilitates rapid recognition of infected cells by specific CD8+ T cells. J Virol (2012) 0.93
Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med (2011) 0.93
Accelerating HIV vaccine development. Nature (2010) 0.93
Cell-intrinsic IL-27 and gp130 cytokine receptor signaling regulates virus-specific CD4⁺ T cell responses and viral control during chronic infection. Immunity (2013) 0.93
Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials (2014) 0.93
Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS One (2011) 0.92
Limited immunogenicity of HIV CD8+ T-cell epitopes in acute Clade C virus infection. J Infect Dis (2011) 0.92
PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. J Clin Invest (2013) 0.90
New approaches to design HIV-1 T-cell vaccines. Curr Opin HIV AIDS (2010) 0.88
Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol (2013) 0.85
Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies. Retrovirology (2014) 0.84
Antigen replacement of domains D2 and D3 in flagellin promotes mucosal IgA production and attenuates flagellin-induced inflammatory response after intranasal immunization. Hum Vaccin Immunother (2013) 0.84
Simian immunodeficiency virus-specific CD4+ T cells from successful vaccinees target the SIV Gag capsid. Immunogenetics (2010) 0.84
Protection against SHIV-KB9 infection by combining rDNA and rFPV vaccines based on HIV multiepitope and p24 protein in Chinese rhesus macaques. Clin Dev Immunol (2012) 0.82
A Critical Role of IL-21-Induced BATF in Sustaining CD8-T-Cell-Mediated Chronic Viral Control. Cell Rep (2015) 0.80
Determination of the Membrane Permeability to Water of Human Vaginal Mucosal Immune Cells at Subzero Temperatures Using Differential Scanning Calorimetry. Biopreserv Biobank (2016) 0.80
Construction of a live-attenuated HIV-1 vaccine through genetic code expansion. Angew Chem Int Ed Engl (2014) 0.80
The effects of chronic binge alcohol on the genital microenvironment of simian immunodeficiency virus-infected female rhesus macaques. AIDS Res Hum Retroviruses (2014) 0.80
A study of the osmotic characteristics, water permeability, and cryoprotectant permeability of human vaginal immune cells. Cryobiology (2016) 0.79
Elite control of HIV: p21 (waf-1/cip-1) at its best. Cell Cycle (2011) 0.78
Molecular characterization of the cervical and systemic B-cell repertoire: Unique, yet overlapping, immune compartments of an HIV-1 resistant individual. MAbs (2011) 0.78
HIV vaccines: can CD4+ T cells be of help? Hum Vaccin Immunother (2012) 0.78
In Vivo and in Vitro Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4(+) T Cells. Mol Cell Proteomics (2017) 0.78
Intraepithelial γδ T cells remain increased in the duodenum of AIDS patients despite antiretroviral treatment. PLoS One (2012) 0.78
Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. J Virol (2015) 0.77
High frequency of transmitted HIV-1 Gag HLA class I-driven immune escape variants but minimal immune selection over the first year of clade C infection. PLoS One (2015) 0.77
Designing synthetic vaccines for HIV. Expert Rev Vaccines (2015) 0.77
Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method. BMC Bioinformatics (2014) 0.76
A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells. PLoS One (2011) 0.76
Association between HIV-1 coreceptor usage and resistance to broadly neutralizing antibodies. J Acquir Immune Defic Syndr (2014) 0.76
Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications. J Transl Med (2011) 0.76
Designer antigens for elicitation of broadly neutralizing antibodies against HIV. Clin Transl Immunology (2014) 0.75
Interference of retroviral envelope with vaccine-induced CD8(+) T cell responses is relieved by co-administration of cytokine-encoding vectors. Retrovirology (2017) 0.75
Dendritic Cell Targeting Effectively Boosts T Cell Responses Elicited by an HIV Multiepitope DNA Vaccine. Front Immunol (2017) 0.75
Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory. Int J Mol Sci (2016) 0.75
Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV. Infect Dis Obstet Gynecol (2014) 0.75
A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Front Immunol (2017) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell (2009) 20.29
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol (1994) 10.03
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science (2002) 9.17
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med (2006) 8.18
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature (2005) 6.78
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity (2007) 6.66
Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol (2009) 6.62
Redefining chronic viral infection. Cell (2009) 6.30
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2008) 6.17
Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2008) 5.94
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Coordination of early protective immunity to viral infection by regulatory T cells. Science (2008) 5.33
The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathog (2008) 5.28
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 5.14
Targeting early infection to prevent HIV-1 mucosal transmission. Nature (2010) 5.05
IL-21 is required to control chronic viral infection. Science (2009) 4.80
B cells in HIV infection and disease. Nat Rev Immunol (2009) 4.73
A vital role for interleukin-21 in the control of a chronic viral infection. Science (2009) 4.55
Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science (2009) 4.45
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 4.41
Metagenomic analysis of human diarrhea: viral detection and discovery. PLoS Pathog (2008) 4.29
Herpesvirus latency confers symbiotic protection from bacterial infection. Nature (2007) 4.27
Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog (2009) 4.24
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14
CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature (2009) 4.03
IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science (2009) 3.90
HIV vaccine research: the way forward. Science (2008) 3.86
Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science (2009) 3.69
Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med (2007) 3.66
Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet (1996) 3.65
Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med (2009) 3.25
Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med (2008) 3.20
Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med (2008) 2.81
HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol (2009) 2.80
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65
Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med (2004) 2.64
CpG methylation controls reactivation of HIV from latency. PLoS Pathog (2009) 2.51
Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med (2009) 2.41
AIDS: time to turn to basic science. Nature (1994) 2.39
Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol (2009) 2.38
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination. J Immunol (2008) 2.35
IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med (2008) 2.20
T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol (2009) 2.17
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12
A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol (2009) 2.10
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science (2008) 1.97
Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity (2009) 1.94
Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res (2009) 1.94
IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A (2008) 1.84
Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol (1998) 1.83
Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol (2009) 1.80
A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A (2009) 1.76
Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol (2005) 1.75
Immune control of the number and reactivation phenotype of cells latently infected with a gammaherpesvirus. J Virol (2002) 1.74
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med (2006) 1.72
Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog (2008) 1.69
Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys. J Clin Invest (2008) 1.57
Protective anti-reovirus monoclonal antibodies and their effects on viral pathogenesis. J Virol (1993) 1.55
Profound CD4+/CCR5+ T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis. J Exp Med (2009) 1.51
Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol (2006) 1.36
Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. Proc Natl Acad Sci U S A (1995) 1.33
Transmission and long-term stability of compensated CD8 escape mutations. J Virol (2008) 1.29
Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci U S A (2004) 1.20
Not all cytokine-producing CD8+ T cells suppress simian immunodeficiency virus replication. J Virol (2006) 1.19
HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr (1994) 1.14
Antibody-independent control of gamma-herpesvirus latency via B cell induction of anti-viral T cell responses. PLoS Pathog (2006) 1.08
Race between retroviral spread and CD4+ T-cell response determines the outcome of acute Friend virus infection. J Virol (2009) 1.05
Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells. PLoS One (2008) 1.01
Identification of enteroviruses in naturally infected captive primates. J Clin Microbiol (2008) 0.99
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity (2007) 6.66
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis (2008) 6.43
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30
Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS (2003) 5.28
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med (2004) 4.52
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 4.41
Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 4.37
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS (2011) 3.95
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature (2010) 3.57
Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med (2008) 3.48
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35
Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med (2010) 3.32
CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol (2007) 3.31
A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol (2006) 3.20
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood (2009) 3.14
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99
Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis (2003) 2.92
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
A microchip CD4 counting method for HIV monitoring in resource-poor settings. PLoS Med (2005) 2.90
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol (2005) 2.84
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med (2003) 2.79
CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 2.77
High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS (2007) 2.73
Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol (2008) 2.72
HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med (2012) 2.72
Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol (2009) 2.70
Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS (2008) 2.65
Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis (2008) 2.64
Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis (2009) 2.60
A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods (2008) 2.56
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol (2009) 2.51
Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J Exp Med (2009) 2.39
Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc Natl Acad Sci U S A (2011) 2.37
HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet (2004) 2.36
Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol (2008) 2.32
Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol (2007) 2.26
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol (2005) 2.24
Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol (2004) 2.21
Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med (2003) 2.17
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
Limited durability of viral control following treated acute HIV infection. PLoS Med (2004) 2.16
Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol (2002) 2.14
HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol (2008) 2.14
PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol (2009) 2.14
STI and beyond: the prospects of boosting anti-HIV immune responses. Trends Immunol (2002) 2.12
Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med (2012) 2.12
Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10
Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One (2008) 2.06
TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol (2012) 2.04
De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 2.04
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 2.03
High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol (2007) 2.01
Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity (2013) 2.00
Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J Virol Methods (2006) 1.99
Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol (2006) 1.99
Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol (2002) 1.98
Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol (2006) 1.98
Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol (2010) 1.97
HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol (2008) 1.95
Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol (2008) 1.94
HIV and HLA class I: an evolving relationship. Immunity (2012) 1.91
HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol (2010) 1.90
HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS (2004) 1.89
A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J Exp Med (2007) 1.88
Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS (2004) 1.85
Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood (2011) 1.85
Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep (2012) 1.84
Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82
Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol (2010) 1.81
The role of IFN-gamma Elispot assay in HIV vaccine research. Nat Protoc (2009) 1.80
Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS (2003) 1.80